# A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

> **NCT03329092** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 422 (actual)

## Conditions studied

- Complicated Intra-abdominal Infection
- Hosptial Acquired Pneumonia
- Ventilator Associated Pneumonia

## Interventions

- **DRUG:** ATM-AVI
- **DRUG:** MTZ
- **DRUG:** MER
- **DRUG:** COL

## Key facts

- **NCT ID:** NCT03329092
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-05
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329092, "A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03329092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*